FDG-PET for esophageal cancer and colorectal cancer

Koji Murakami

Research output: Contribution to journalArticle

Abstract

This article outlines the significance of using FDG-PET for patients with esophageal cancer and colorectal cancer according to object, which includes staging, therapeutic monitoring, detection of lymphnodes or distant metastases, and early detection of recurrence. FDG-PET is useful for diagnosing lymphnode metastases that are difficult to be judge only by its size, or in cases with an elevated serum tumor marker in spite of negative findings by other imaging modalities. Conversely, as FDG-PETs sometime produce false positive and false negative findings, the final decision should be based not only on PET but also on the results of all other imaging modalities. Though reimbursement is available for colorectal cancer, it is not available for esophageal cancer. As FDG-PET is useful, it would be desirable to have reimbursement available for esophageal cancer as well.

Original languageEnglish
Pages (from-to)229-235
Number of pages7
JournalBiotherapy
Volume17
Issue number3
Publication statusPublished - 2003 May
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Tumor Biomarkers
Biomarkers
Recurrence
Therapeutics

Keywords

  • Colorectal cancer
  • Esophageal cancer
  • FDG-PET

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Murakami, K. (2003). FDG-PET for esophageal cancer and colorectal cancer. Biotherapy, 17(3), 229-235.

FDG-PET for esophageal cancer and colorectal cancer. / Murakami, Koji.

In: Biotherapy, Vol. 17, No. 3, 05.2003, p. 229-235.

Research output: Contribution to journalArticle

Murakami, K 2003, 'FDG-PET for esophageal cancer and colorectal cancer', Biotherapy, vol. 17, no. 3, pp. 229-235.
Murakami, Koji. / FDG-PET for esophageal cancer and colorectal cancer. In: Biotherapy. 2003 ; Vol. 17, No. 3. pp. 229-235.
@article{bce4b2b0239545aa9f5586dda224e852,
title = "FDG-PET for esophageal cancer and colorectal cancer",
abstract = "This article outlines the significance of using FDG-PET for patients with esophageal cancer and colorectal cancer according to object, which includes staging, therapeutic monitoring, detection of lymphnodes or distant metastases, and early detection of recurrence. FDG-PET is useful for diagnosing lymphnode metastases that are difficult to be judge only by its size, or in cases with an elevated serum tumor marker in spite of negative findings by other imaging modalities. Conversely, as FDG-PETs sometime produce false positive and false negative findings, the final decision should be based not only on PET but also on the results of all other imaging modalities. Though reimbursement is available for colorectal cancer, it is not available for esophageal cancer. As FDG-PET is useful, it would be desirable to have reimbursement available for esophageal cancer as well.",
keywords = "Colorectal cancer, Esophageal cancer, FDG-PET",
author = "Koji Murakami",
year = "2003",
month = "5",
language = "English",
volume = "17",
pages = "229--235",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "3",

}

TY - JOUR

T1 - FDG-PET for esophageal cancer and colorectal cancer

AU - Murakami, Koji

PY - 2003/5

Y1 - 2003/5

N2 - This article outlines the significance of using FDG-PET for patients with esophageal cancer and colorectal cancer according to object, which includes staging, therapeutic monitoring, detection of lymphnodes or distant metastases, and early detection of recurrence. FDG-PET is useful for diagnosing lymphnode metastases that are difficult to be judge only by its size, or in cases with an elevated serum tumor marker in spite of negative findings by other imaging modalities. Conversely, as FDG-PETs sometime produce false positive and false negative findings, the final decision should be based not only on PET but also on the results of all other imaging modalities. Though reimbursement is available for colorectal cancer, it is not available for esophageal cancer. As FDG-PET is useful, it would be desirable to have reimbursement available for esophageal cancer as well.

AB - This article outlines the significance of using FDG-PET for patients with esophageal cancer and colorectal cancer according to object, which includes staging, therapeutic monitoring, detection of lymphnodes or distant metastases, and early detection of recurrence. FDG-PET is useful for diagnosing lymphnode metastases that are difficult to be judge only by its size, or in cases with an elevated serum tumor marker in spite of negative findings by other imaging modalities. Conversely, as FDG-PETs sometime produce false positive and false negative findings, the final decision should be based not only on PET but also on the results of all other imaging modalities. Though reimbursement is available for colorectal cancer, it is not available for esophageal cancer. As FDG-PET is useful, it would be desirable to have reimbursement available for esophageal cancer as well.

KW - Colorectal cancer

KW - Esophageal cancer

KW - FDG-PET

UR - http://www.scopus.com/inward/record.url?scp=0038802723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038802723&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0038802723

VL - 17

SP - 229

EP - 235

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 3

ER -